Literature DB >> 18091323

Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors.

Hongying Zhang1, Hong Bu, Huijiao Chen, Bing Wei, Weiping Liu, Jia Guo, Fengyuan Li, Dianying Liao, Yuan Tang, Zhang Zhang.   

Abstract

Most adrenocortical tumors (ACTs) can be diagnosed directly by a combination of morphologic features and clinical findings. However, sometimes it may be difficult to distinguish ACTs from other neoplasms such as pheochromocytomas and some metastatic tumors, particularly for small biopsy specimens because they may be morphologically similar. Expression of calretinin has recently been suggested as a valuable immunomarker for the differential diagnosis between ACTs and other tumors; however, its diagnostic value is still under debate. To determine the diagnostic value of calretinin in Chinese patients with adrenocortical and non-ACTs, we employed both polyclonal and monoclonal anticalretinin to characterize the expression of calretinin in adrenal tissues and compared its expression with that of inhibin alpha, Melan-A, cytokeratin, or CD99 by immunohistochemistry in tissue microarrays and standard tissue sections of 414 specimens. Our results revealed that calretinin was expressed by adrenocortical cells, but not by the other cells tested and the percentage of calretinin-positive ACTs reached 99% when stained with polyclonal antibodies, which was higher than that with monoclonal anticalretinin (91.3%), anti-Melan-A (90.3%), antiinhibin alpha (81.6%). In addition, our results also revealed that ACTs were stained by cytokeratin (AE1/AE3) with variable degrees (58.7%). Furthermore, unlike anti-Melan-A that stained all metastatic malignant melanoma, anticalretinin did not recognize other tested tumors. Therefore, immunohistologic staining with polyclonal anticalretinin is more sensitive than other antibodies tested for the diagnosis of ACTs. However, monoclonal anticalretinin appeared to be more specific. Importantly, our data suggested that the fried-egg-like staining pattern, but not the mere cytoplasmic staining, was characteristic of anticalretinin staining in adrenocortical tissues. Notably, a few anticalretinin negative-ACTs were stained by other immunomarkers that we tested. Thus, the combinational characterization of calretinin (either by polyclonal or monoclonal antibody), inhibin alpha, and Melan-A expression is of great significance in the differential diagnosis of ACTs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18091323     DOI: 10.1097/PAI.0b013e318032cf56

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  5 in total

1.  Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases.

Authors:  Ankur R Sangoi; Mika Fujiwara; Robert B West; Kelli D Montgomery; Joseph V Bonventre; John P Higgins; Robert V Rouse; Neriman Gokden; Jesse K McKenney
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

Review 2.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

3.  Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor.

Authors:  Hongmei Li; Ondrej Hes; Gregory T MacLennan; Daniel C Eastwood; Kenneth A Iczkowski
Journal:  Virchows Arch       Date:  2015-02-19       Impact factor: 4.064

4.  DLK is a novel immunohistochemical marker for adrenal gland tumors.

Authors:  Eszter Turányi; Katalin Dezso; Sándor Paku; Peter Nagy
Journal:  Virchows Arch       Date:  2009-08-14       Impact factor: 4.064

5.  A rare coexistence of non-functional adrenocortical carcinoma and multicentric papillary thyroid microcarcinoma: a case report.

Authors:  Melia Karakose; Oguz Hasdemir; Erman Cakal; Tuncay Delibasi
Journal:  J Med Case Rep       Date:  2013-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.